Massachusetts Financial Services Co. MA Purchases 14,226 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD)

Massachusetts Financial Services Co. MA grew its position in shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) by 2.8% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 522,375 shares of the company’s stock after buying an additional 14,226 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Prelude Therapeutics were worth $1,990,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Acadian Asset Management LLC increased its holdings in Prelude Therapeutics by 42.7% during the 1st quarter. Acadian Asset Management LLC now owns 22,110 shares of the company’s stock valued at $104,000 after purchasing an additional 6,615 shares during the period. Kennedy Capital Management LLC purchased a new position in shares of Prelude Therapeutics during the first quarter valued at approximately $119,000. Pale Fire Capital SE raised its holdings in shares of Prelude Therapeutics by 106.6% during the fourth quarter. Pale Fire Capital SE now owns 63,581 shares of the company’s stock valued at $271,000 after acquiring an additional 32,800 shares in the last quarter. Vanguard Group Inc. lifted its stake in Prelude Therapeutics by 1.0% in the first quarter. Vanguard Group Inc. now owns 1,016,999 shares of the company’s stock worth $4,821,000 after acquiring an additional 10,143 shares during the period. Finally, Boxer Capital LLC increased its position in Prelude Therapeutics by 2.9% during the 4th quarter. Boxer Capital LLC now owns 2,568,287 shares of the company’s stock valued at $10,967,000 after purchasing an additional 73,269 shares during the period. 79.72% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on PRLD shares. JMP Securities reaffirmed a “market outperform” rating and issued a $7.00 target price on shares of Prelude Therapeutics in a research report on Monday, September 16th. HC Wainwright upgraded Prelude Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday. Finally, Barclays lowered Prelude Therapeutics from an “equal weight” rating to an “underweight” rating and set a $3.00 price target on the stock. in a research report on Thursday, June 20th.

Prelude Therapeutics Stock Performance

Shares of NASDAQ PRLD opened at $2.55 on Monday. The company has a 50 day simple moving average of $5.10 and a two-hundred day simple moving average of $4.47. Prelude Therapeutics Incorporated has a fifty-two week low of $1.66 and a fifty-two week high of $6.80. The company has a market capitalization of $140.30 million, a price-to-earnings ratio of -1.36 and a beta of 1.52.

Prelude Therapeutics (NASDAQ:PRLD) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.46) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.46). On average, analysts forecast that Prelude Therapeutics Incorporated will post -1.85 earnings per share for the current fiscal year.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.